{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:39:25Z","timestamp":1785400765405,"version":"3.56.0"},"posted":{"date-parts":[[2025,12,16]]},"group-title":"Pharmacology and Toxicology","reference-count":89,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nd\/4.0\/"}],"funder":[{"award":["GM152417"],"award-info":[{"award-number":["GM152417"]}],"id":[{"id":"https:\/\/ror.org\/04q48ey07","id-type":"ROR","asserted-by":"publisher"}]},{"award":["GM140223"],"award-info":[{"award-number":["GM140223"]}],"id":[{"id":"https:\/\/ror.org\/04q48ey07","id-type":"ROR","asserted-by":"publisher"}]},{"award":["DK120623"],"award-info":[{"award-number":["DK120623"]}],"id":[{"id":"https:\/\/ror.org\/00adh9b73","id-type":"ROR","asserted-by":"publisher"}]},{"name":"national institutites of health office of the director","award":["S10OD034245"],"award-info":[{"award-number":["S10OD034245"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,12,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>\n                    Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent condition characterized by fat build-up in the liver and ranges from benign steatosis to progression to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis and end-stage liver disease including hepatocellular carcinoma, representing a significant cause of chronic liver disease globally.\n                    <jats:sup>1,2<\/jats:sup>\n                    Current treatment options are limited, primarily relying on lifestyle modifications, highlighting an urgent need for novel therapeutic strategies.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A Cell Painting-style high-content screening phenotypic assay was employed using the PH5CH8 human hepatocyte cell line to identify small molecules capable of modulating induced hepatic steatosis. The Plex Research artificial intelligence (AI) platform was utilized for target deconvolution of the lead hit compound, \u03b1-terthienyl. In vivo efficacy was assessed in a diet-induced obesity (DIO) C57BL\/6J mouse model of MASLD. Biochemical assays and molecular docking simulations were performed to validate predicted target interactions.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\n                    Phenotypic screening identified 15 chemical probes\/drugs that elicit dose-responsive inhibition of steatosis, and 16 that exacerbate steatosis, which could contribute to worsening of the disease clinically. \u03b1-terthienyl, a plant-derived natural product, was identified as a potent and non-toxic inhibitor of steatosis in PH5CH8 cells with an EC\n                    <jats:sub>50<\/jats:sub>\n                    of 106 nM. In vivo, \u03b1-terthienyl administration to diet-induced obesity (60% fat diet) mice significantly reduced hepatic steatosis histologically, improved glucose tolerance, and favorably modulated serum biomarkers including ALT and AST. AI-driven analysis predicted dipeptidyl peptidase 4 (DPP-IV) and 17-beta hydroxysteroid dehydrogenase 13 (HSD17\u03b213) as potential molecular targets of \u03b1-terthienyl. Biochemical inhibition of DPP-IV was observed and an oxidized \u03b1-terthienyl analog inhibited HSD17\u03b213. Molecular docking supported these predictions, indicating binding to DPP-IV and HSD17\u03b213.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study demonstrates the successful application of phenotypic screening integrated with AI-driven target deconvolution to identify compounds and drugs that ameliorate or exacerbate hepatic steatosis. \u03b1-terthienyl was identified as a novel modulator of hepatic steatosis with in vivo efficacy in a MASLD model. Our findings suggest a dual-target mechanism involving DPP-IV and HSD17\u03b213, potentially engaged by the parent compound and its metabolite, respectively, offering a promising polypharmacological approach for MASLD treatment.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2025.12.12.693988","type":"posted-content","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T16:15:22Z","timestamp":1765901722000},"source":"Crossref","is-referenced-by-count":2,"title":["Phenotypic Screening Coupled with AI-Driven Target Deconvolution Identifies \u03b1-Terthienyl as a Dual DPP-IV\/HSD17\u03b213 Modulator with Efficacy in a Mouse Model of MASLD"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5974-554X","authenticated-orcid":false,"given":"Kathryn M.","family":"Hoegeman","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7085-7582","authenticated-orcid":false,"given":"Jesse W.","family":"Wotring","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109"},{"name":"Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9484-0152","authenticated-orcid":false,"given":"Reid","family":"Fursmidt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7103-6241","authenticated-orcid":false,"given":"Jedidiah","family":"Gaetz","sequence":"additional","affiliation":[{"name":"Plex Research Inc., Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4266-1483","authenticated-orcid":false,"given":"Ehab M.","family":"Khalil","sequence":"additional","affiliation":[{"name":"Plex Research Inc., Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3031-0856","authenticated-orcid":false,"given":"Douglas W.","family":"Selinger","sequence":"additional","affiliation":[{"name":"Plex Research Inc., Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9615-3738","authenticated-orcid":false,"given":"Ilya","family":"Kovalenko","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3133-8756","authenticated-orcid":false,"given":"Tracey L.","family":"Schultz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6542-0474","authenticated-orcid":false,"given":"Sean M.","family":"McCarty","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109"},{"name":"Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3128-5331","authenticated-orcid":false,"given":"Matthew J.","family":"O\u2019Meara","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109"},{"name":"Gilbert S. Omenn Department of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7852-1733","authenticated-orcid":false,"given":"Martin C.","family":"Clasby","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9244-5888","authenticated-orcid":false,"given":"Jonathan Z.","family":"Sexton","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109"},{"name":"Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026010105553399000_2025.12.12.693988v2.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2017.08.003"},{"key":"2026010105553399000_2025.12.12.693988v2.2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25762"},{"key":"2026010105553399000_2025.12.12.693988v2.3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001834"},{"key":"2026010105553399000_2025.12.12.693988v2.4","doi-asserted-by":"publisher","DOI":"10.2337\/dsi23-0010"},{"key":"2026010105553399000_2025.12.12.693988v2.5","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.cgh.2024.03.028","article-title":"Phenotypes of metabolic dysfunction-associated steatotic liver disease-associated hepatocellular carcinoma","volume":"22","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol"},{"key":"2026010105553399000_2025.12.12.693988v2.6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431"},{"key":"2026010105553399000_2025.12.12.693988v2.7","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90235-6"},{"key":"2026010105553399000_2025.12.12.693988v2.8","doi-asserted-by":"publisher","DOI":"10.1159\/000282081"},{"key":"2026010105553399000_2025.12.12.693988v2.9","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840110114"},{"key":"2026010105553399000_2025.12.12.693988v2.10","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.72"},{"key":"2026010105553399000_2025.12.12.693988v2.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra011775"},{"key":"2026010105553399000_2025.12.12.693988v2.12","doi-asserted-by":"publisher","DOI":"10.1038\/35007508"},{"key":"2026010105553399000_2025.12.12.693988v2.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04556.x"},{"key":"2026010105553399000_2025.12.12.693988v2.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2024.02.007"},{"key":"2026010105553399000_2025.12.12.693988v2.15","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.05.041"},{"key":"2026010105553399000_2025.12.12.693988v2.16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21327"},{"key":"2026010105553399000_2025.12.12.693988v2.17","doi-asserted-by":"crossref","unstructured":"Michalopoulou, E. , et al. The triad of risk: Linking MASLD, cardiovascular disease and type 2 diabetes; From pathophysiology to treatment. J. Clin. Med. 14, (2025).","DOI":"10.3390\/jcm14020428"},{"key":"2026010105553399000_2025.12.12.693988v2.18","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02045-0"},{"key":"2026010105553399000_2025.12.12.693988v2.19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.17925\/EE.2023.19.1.60","article-title":"Resmetirom: An orally administered, smallmolecule, liver-directed, \u03b2-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"19","year":"2023","journal-title":"touchREV. Endocrinol."},{"key":"2026010105553399000_2025.12.12.693988v2.20","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.111"},{"key":"2026010105553399000_2025.12.12.693988v2.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2012.12.022"},{"key":"2026010105553399000_2025.12.12.693988v2.22","doi-asserted-by":"publisher","DOI":"10.1101\/2024.12.17.629024"},{"key":"2026010105553399000_2025.12.12.693988v2.23","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/s41592-025-02753-9","article-title":"Morphological map of under- and overexpression of genes in human cells","volume":"22","year":"2025","journal-title":"Nat. Methods"},{"key":"2026010105553399000_2025.12.12.693988v2.24","doi-asserted-by":"crossref","unstructured":"Nakamura, T. , et al. Pathogenic mechanisms of metabolic dysfunction-associated steatotic liver disease (MASLD)-associated hepatocellular carcinoma. Cells 14, (2025).","DOI":"10.3390\/cells14060428"},{"key":"2026010105553399000_2025.12.12.693988v2.25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1021\/acsmedchemlett.9b00039","article-title":"Harnessing polypharmacology with medicinal chemistry","volume":"10","year":"2019","journal-title":"ACS Med. Chem. Lett"},{"key":"2026010105553399000_2025.12.12.693988v2.26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-pharmtox-061324-011832","article-title":"Weight loss blockbuster development: A role for unimolecular polypharmacology","volume":"65","year":"2025","journal-title":"Annu. Rev. Pharmacol. Toxicol"},{"key":"2026010105553399000_2025.12.12.693988v2.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2005.10.023"},{"key":"2026010105553399000_2025.12.12.693988v2.28","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-020-01018-x"},{"key":"2026010105553399000_2025.12.12.693988v2.29","doi-asserted-by":"crossref","unstructured":"Stirling, D. R. , et al. CellProfiler 4: improvements in speed, utility and usability. BMC Bioinformatics 22, 433 (2021).","DOI":"10.1186\/s12859-021-04344-9"},{"key":"2026010105553399000_2025.12.12.693988v2.30","doi-asserted-by":"publisher","DOI":"10.1145\/1656274.1656280"},{"key":"2026010105553399000_2025.12.12.693988v2.31","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.1c00203"},{"key":"2026010105553399000_2025.12.12.693988v2.32","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2016.051"},{"key":"2026010105553399000_2025.12.12.693988v2.33","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-430-8_27"},{"key":"2026010105553399000_2025.12.12.693988v2.34","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00291.2013"},{"key":"2026010105553399000_2025.12.12.693988v2.35","unstructured":"Nivsarkar, M. , Cherian, B. & Padh, H . Alpha-terthienyl: A plant-derived new generation insecticide. Current Science (2001)."},{"key":"2026010105553399000_2025.12.12.693988v2.36","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20342"},{"key":"2026010105553399000_2025.12.12.693988v2.37","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0782"},{"key":"2026010105553399000_2025.12.12.693988v2.38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.toxicon.2018.11.429","article-title":"A review of cardiac glycosides: Structure, toxicokinetics, clinical signs, diagnosis and antineoplastic potential","volume":"158","year":"2019","journal-title":"Toxicon"},{"key":"2026010105553399000_2025.12.12.693988v2.39","doi-asserted-by":"crossref","unstructured":"Citarella, A. , Vittorio, S. , Dank, C. & Ielo, L . Syntheses, reactivity, and biological applications of coumarins. Front. Chem. 12, 1362992 (2024).","DOI":"10.3389\/fchem.2024.1362992"},{"key":"2026010105553399000_2025.12.12.693988v2.40","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jpba.2018.06.055","article-title":"Stressed degradation studies of domiphen bromide by LC-ESI-MS\/MS identify a novel promising antimicrobial agent","volume":"159","year":"2018","journal-title":"J. Pharm. Biomed. Anal"},{"key":"2026010105553399000_2025.12.12.693988v2.41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1017496108"},{"key":"2026010105553399000_2025.12.12.693988v2.42","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1093\/abbs\/gmab103","article-title":"Small-molecule inhibitor LF3 restrains the development of pulmonary hypertension through the Wnt\/\u03b2-catenin pathway","volume":"53","year":"2021","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai"},{"key":"2026010105553399000_2025.12.12.693988v2.43","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/s42255-019-0122-z","article-title":"Cardiac glycosides are broad-spectrum senolytics","volume":"1","year":"2019","journal-title":"Nat. Metab"},{"key":"2026010105553399000_2025.12.12.693988v2.44","doi-asserted-by":"publisher","DOI":"10.1177\/000331979204300602"},{"key":"2026010105553399000_2025.12.12.693988v2.45","doi-asserted-by":"crossref","first-page":"9528","DOI":"10.1038\/s41598-021-89074-x","article-title":"Periplocin and cardiac glycosides suppress the unfolded protein response","volume":"11","year":"2021","journal-title":"Sci. Rep"},{"key":"2026010105553399000_2025.12.12.693988v2.46","doi-asserted-by":"crossref","unstructured":"Siva, S. , et al. Encompassment of phthalyl sulfacetamide in \u03b1- and \u03b2-cyclodextrin using ultrasonication: Physicochemical and computational modeling investigations. J. Mol. Liq. 319, 114184 (2020).","DOI":"10.1016\/j.molliq.2020.114184"},{"key":"2026010105553399000_2025.12.12.693988v2.47","first-page":"1812","article-title":"The effect of Rhodamine B on the cerebellum and brainstem tissue of Rattus norvegicus","volume":"9","year":"2020","journal-title":"J. Public Health Res"},{"key":"2026010105553399000_2025.12.12.693988v2.48","doi-asserted-by":"crossref","first-page":"206","DOI":"10.38212\/2224-6614.1055","article-title":"Food preservative sorbic acid deregulates hepatic fatty acid metabolism","volume":"28","year":"2020","journal-title":"J. Food Drug Anal"},{"key":"2026010105553399000_2025.12.12.693988v2.49","first-page":"171","article-title":"THZ1, a covalent CDK7 inhibitor, enhances gemcitabine-induced cytotoxicity via suppression of Bcl-2 in urothelial carcinoma","volume":"11","year":"2021","journal-title":"Am. J. Cancer Res"},{"key":"2026010105553399000_2025.12.12.693988v2.50","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.molmet.2019.12.003","article-title":"mTORC1 restrains adipocyte lipolysis to prevent systemic hyperlipidemia","volume":"32","year":"2020","journal-title":"Mol. Metab"},{"key":"2026010105553399000_2025.12.12.693988v2.51","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf8271"},{"key":"2026010105553399000_2025.12.12.693988v2.52","doi-asserted-by":"crossref","unstructured":"Ganz, M. , et al. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice. J. Transl. Med. 13, 193 (2015).","DOI":"10.1186\/s12967-015-0552-7"},{"key":"2026010105553399000_2025.12.12.693988v2.53","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s00394-023-03085-0","article-title":"Effects of anti-inflammatory dietary patterns on non-alcoholic fatty liver disease: a systematic literature review","volume":"62","year":"2023","journal-title":"Eur. J. Nutr"},{"key":"2026010105553399000_2025.12.12.693988v2.54","doi-asserted-by":"crossref","unstructured":"Raza, S. , Rajak, S. , Yen, P. M. & Sinha, R. A . Autophagy and hepatic lipid metabolism: mechanistic insight and therapeutic potential for MASLD. NPJ Metab. Health Dis. 2, 19 (2024).","DOI":"10.1038\/s44324-024-00022-5"},{"key":"2026010105553399000_2025.12.12.693988v2.55","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/s41419-022-05444-x","article-title":"Endoplasmic reticulum stress-mediated cell death in liver injury","volume":"13","year":"2022","journal-title":"Cell Death Dis"},{"key":"2026010105553399000_2025.12.12.693988v2.56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39404-6"},{"key":"2026010105553399000_2025.12.12.693988v2.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.05.020"},{"key":"2026010105553399000_2025.12.12.693988v2.58","doi-asserted-by":"publisher","DOI":"10.1111\/febs.12350"},{"key":"2026010105553399000_2025.12.12.693988v2.59","doi-asserted-by":"crossref","unstructured":"Skat-R\u00f8rdam, J. , Lykkesfeldt, J. , Gluud, L. L. & Tveden-Nyborg, P . Mechanisms of drug induced liver injury. Cell. Mol. Life Sci. 82, 213 (2025).","DOI":"10.1007\/s00018-025-05744-3"},{"key":"2026010105553399000_2025.12.12.693988v2.60","doi-asserted-by":"crossref","unstructured":"Tiwari, V. , et al. Insights into medication-induced liver injury: Understanding and management strategies. Toxicol. Rep. 14, 101976 (2025).","DOI":"10.1016\/j.toxrep.2025.101976"},{"key":"2026010105553399000_2025.12.12.693988v2.61","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/S0960-894X(99)00375-3","article-title":"Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives","volume":"9","year":"1999","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"2026010105553399000_2025.12.12.693988v2.62","doi-asserted-by":"publisher","DOI":"10.1021\/tx700430n"},{"key":"2026010105553399000_2025.12.12.693988v2.63","unstructured":"Compton, S. A. , Musso, D. L. , Laudeman, C. , Brenman, J. E. & Sexton, J. Phenylbenzamides of the Niclosamide Chemotype Reverse Fatty Liver Disesae and Improve Liver Metabolomic Signatures in the Murine C57-Diet-Induced Obesity Model. in HEPATOLOGY vol. 68 1037A\u20131038A (WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, 2018)."},{"key":"2026010105553399000_2025.12.12.693988v2.64","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1600-0773.1995.tb01007.x","article-title":"Pharmacokinetics, metabolism and toxicity of the plant-derived photoxin alpha-terthienyl","volume":"77","year":"1995","journal-title":"Pharmacol. Toxicol"},{"key":"2026010105553399000_2025.12.12.693988v2.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2005.12.007"},{"key":"2026010105553399000_2025.12.12.693988v2.66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712191"},{"key":"2026010105553399000_2025.12.12.693988v2.67","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17292"},{"key":"2026010105553399000_2025.12.12.693988v2.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2010.12.013"},{"key":"2026010105553399000_2025.12.12.693988v2.69","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.1038\/s41467-023-40766-0","article-title":"Structural basis of lipid-droplet localization of 17-beta-hydroxysteroid dehydrogenase 13","volume":"14","year":"2023","journal-title":"Nat. Commun"},{"key":"2026010105553399000_2025.12.12.693988v2.70","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2012.36.4.262"},{"key":"2026010105553399000_2025.12.12.693988v2.71","doi-asserted-by":"crossref","first-page":"e70003","DOI":"10.1111\/eci.70003","article-title":"Pharmacological treatment options for metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review","volume":"55","year":"2025","journal-title":"Eur. J. Clin. Invest"},{"key":"2026010105553399000_2025.12.12.693988v2.72","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258"},{"key":"2026010105553399000_2025.12.12.693988v2.73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401755"},{"key":"2026010105553399000_2025.12.12.693988v2.74","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11596-015-1433-2","article-title":"Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease","volume":"35","year":"2015","journal-title":"J. Huazhong Univ. Sci. Technolog. Med. Sci"},{"key":"2026010105553399000_2025.12.12.693988v2.75","doi-asserted-by":"crossref","unstructured":"Zhang, H.-B. , Su, W. , Xu, H. , Zhang, X.-Y. & Guan, Y.-F . HSD17B13: A potential therapeutic target for NAFLD. Front. Mol. Biosci. 8, 824776 (2021).","DOI":"10.3389\/fmolb.2021.824776"},{"key":"2026010105553399000_2025.12.12.693988v2.76","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30350"},{"key":"2026010105553399000_2025.12.12.693988v2.77","doi-asserted-by":"publisher","DOI":"10.1113\/EP092535"},{"key":"2026010105553399000_2025.12.12.693988v2.78","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/liv.14321","article-title":"Genetic variants that associate with cirrhosis have pleiotropic effects on human traits","volume":"40","year":"2020","journal-title":"Liver Int"},{"key":"2026010105553399000_2025.12.12.693988v2.79","doi-asserted-by":"crossref","first-page":"e2217543120","DOI":"10.1073\/pnas.2217543120","article-title":"Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis","volume":"120","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"2026010105553399000_2025.12.12.693988v2.80","doi-asserted-by":"crossref","first-page":"C880","DOI":"10.1152\/ajpcell.00413.2023","article-title":"BI-3231, an enzymatic inhibitor of HSD17B13, reduces lipotoxic effects induced by palmitic acid in murine and human hepatocytes","volume":"326","year":"2024","journal-title":"Am. J. Physiol. Cell Physiol"},{"key":"2026010105553399000_2025.12.12.693988v2.81","unstructured":"Garnsey, M. R. , et al. Design and application of synthetic 17B-HSD13 substrates reveals preserved catalytic activity of protective human variants. Nat. Commun. 16, 297 (2025)."},{"key":"2026010105553399000_2025.12.12.693988v2.82","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2007.03.008"},{"key":"2026010105553399000_2025.12.12.693988v2.83","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.molmet.2017.07.016","article-title":"Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease","volume":"6","year":"2017","journal-title":"Mol. Metab"},{"key":"2026010105553399000_2025.12.12.693988v2.84","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5009\/gnl240407","article-title":"Genetic risk factors for metabolic dysfunction-associated steatotic liver disease","volume":"19","year":"2025","journal-title":"Gut Liver"},{"key":"2026010105553399000_2025.12.12.693988v2.85","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(05)81594-3"},{"key":"2026010105553399000_2025.12.12.693988v2.86","doi-asserted-by":"publisher","DOI":"10.1021\/ja00020a089"},{"key":"2026010105553399000_2025.12.12.693988v2.87","doi-asserted-by":"publisher","DOI":"10.1007\/s43440-023-00501-4"},{"key":"2026010105553399000_2025.12.12.693988v2.88","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1038\/s41598-025-86166-w","article-title":"A novel approach for target deconvolution from phenotype-based screening using knowledge graph","volume":"15","year":"2025","journal-title":"Sci. Rep"},{"key":"2026010105553399000_2025.12.12.693988v2.89","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.5b00364"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2025.12.12.693988","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T13:55:46Z","timestamp":1767275746000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2025.12.12.693988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":89,"URL":"https:\/\/doi.org\/10.64898\/2025.12.12.693988","relation":{},"subject":[],"published":{"date-parts":[[2025,12,16]]},"subtype":"preprint"}}